IP Library Granted Patent US 7,271,274
Granted Patent B2
US 7,271,274 · App. 11/111,196 · Granted Sep 18, 2007

Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,271,274
App. No.
11/111,196
Granted
Sep 18, 2007
Kind
B2
Abstract

The invention relates to compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds, wherein the compounds are of the following Formulas: or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein the substituents are defined in the application. The invention further provides methods of treatment of inflammatory disorders by administering the compounds.

Claims (40)

1. A compound of Formula II

or a pharmaceutically acceptable salt or ester thereof, wherein:

Y is selected from the group consisting of:

or a compound selected from the group consisting of

or a pharmaceutically acceptable salt or ester thereof.

2. The compound of claim 1 wherein the compound is a compound of Formula II wherein

Y is

or a pharmaceutically acceptable salt or ester thereof.

3. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

4. A method for the treatment of an inflammatory disorder, comprising administering an effective amount of a compound of claim 1 .

5. The method of claim 4 , wherein the disorder is arthritis.

6. The method of claim 4 , wherein the disorder is rheumatoid arthritis.

7. The method of claim 4 , wherein the disorder is asthma.

8. The method of claim 4 , wherein the disorder is allergic rhinitis.

9. The method of claim 4 , wherein the disorder is chronic obstructive pulmonary disease.

10. The method of claim 4 , wherein the disorder is atherosclerosis.

11. The method of claim 4 , wherein the disorder is restenosis.

12. A method for inhibiting the expression of VCAM-1, comprising administering an effective amount of a compound of claim 1 .

13. The compound of claim 1 wherein the compound is a compound of Formula II and Y is

or a pharmaceutically acceptable salt or ester thereof.

14. The compound of claim 1 wherein the compound is:

or a pharmaceutically acceptable salt or ester thereof.

15. The compound of claim 1 wherein the compound is:

or a pharmaceutically acceptable salt or ester thereof.

16. The compound of claim 1 wherein the compound is:

or a pharmaceutically acceptable salt or ester thereof.

17. The pharmaceutical composition of claim 3 , in a form suitable for oral, parenteral, intravenous, intradermal, transdermal, subcutaneous or topical administration.

18. The pharmaceutical composition of claim 3 , wherein the compound is in the form of a dosage unit.

19. The pharmaceutical composition of claim 3 , wherein the dosage unit contains about 0.5–1000 mg of the compound.

20. The pharmaceutical composition of claim 3 , in the form of a tablet or capsule.

21. The pharmaceutical composition of claim 3 , wherein the compound is a compound of Formula II

or a pharmaceutically acceptable salt or ester thereof.

22. The pharmaceutical composition of claim 3 , wherein the compound is a compound of Formula II

or a pharmaceutically acceptable salt or ester thereof.

23. The pharmaceutical composition of claim 3 , wherein the compound is

or a pharmaceutically acceptable salt or ester thereof.

24. The pharmaceutical composition of claim 3 , wherein the compound is

or a pharmaceutically acceptable salt or ester thereof.

25. The pharmaceutical composition of claim 3 , wherein the compound is

or a pharmaceutically acceptable salt or ester thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2010
From: ATHEROGENICS, INC.
To: CRABTREE ACQUISITION CO, LLC
Reel/Frame 024933/0616 →
CHANGE OF NAME Recorded Sep 3, 2010
From: CRABTREE ACQUISITION CO, LLC
To: SALUTRIA PHARMACEUTICALS LLC
Reel/Frame 024933/0651 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2007
From: WEINGARTEN, M. DAVID
To: ATHEROGENICS, INC.
Reel/Frame 019004/0583 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2006
From: MENG, CHARLES Q.; SIKORSKI, JAMES A.
To: ATHEROGENICS, INC.
Reel/Frame 018574/0820 →